Who are Dabigatran + Ticagrelor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OAC + clopicogrel, Dabigatran + clopidogrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dabigatran-ticagrelor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Dabigatran + Ticagrelor — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dabigatran + Ticagrelor (Dabigatran + Ticagrelor) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant + antiplatelet agent combination. Area: Cardiovascular.

marketed Anticoagulant + antiplatelet agent combination Thrombin (Factor IIa) and P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Dabigatran + Ticagrelor (Dabigatran + Ticagrelor) — Zuyderland Medisch Centrum. This combination uses dabigatran (a direct thrombin inhibitor) and ticagrelor (a P2Y12 platelet inhibitor) together to provide dual anticoagulant and antiplatelet effects for thrombotic prevention.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dabigatran + Ticagrelor TARGET	Dabigatran + Ticagrelor	Zuyderland Medisch Centrum	marketed	Anticoagulant + antiplatelet agent combination	Thrombin (Factor IIa) and P2Y12 receptor
OAC + clopicogrel	OAC + clopicogrel	St. Antonius Hospital	marketed	Anticoagulant + antiplatelet agent combination	Coagulation cascade (OAC) and P2Y12 receptor (clopidogrel)
Dabigatran + clopidogrel	Dabigatran + clopidogrel	Zuyderland Medisch Centrum	marketed	Anticoagulant + antiplatelet agent combination	Thrombin (Factor IIa) and P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant + antiplatelet agent combination class)

Zuyderland Medisch Centrum · 2 drugs in this class
St. Antonius Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dabigatran + Ticagrelor — Competitive Intelligence Brief. https://druglandscape.com/ci/dabigatran-ticagrelor. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing